Alnylam Pharmaceuticals, Inc. (ALNY)
Alnylam Pharmaceuticals, Inc. Net Debt to Free Cash Flow
| Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Debt to Free Cash Flow | 1.4x | 3.9x | 7.0x | (2.4x) | (7.9x) | 3.7x | 2.6x | 1.7x | 1.8x | 4.8x | 5.6x | 6.6x | 2.1x | 3.4x | 1.5x | 2.3x | 2.0x | 0.3x | (0.7x) | 5.8x |
Alnylam Pharmaceuticals, Inc. (ALNY) Net Debt to Free Cash Flow comparison analysis
ALNY key stats
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Jan 2025.
investors
worldwide
FAQ
1) What is Alnylam Pharmaceuticals, Inc.'s Net Debt to Free Cash Flow?
As of today, Microsoft Corp's last 12-month Net Debt to Free Cash Flow is (91.5x), based on the financial report for Sep 30, 2024 (Q3 2024). The average annual Net Debt to Free Cash Flow for Alnylam Pharmaceuticals, Inc. have been (3.4x) over the past three years, and (1.9x) over the past five years.
2) Is Alnylam Pharmaceuticals, Inc.'s Net Debt to Free Cash Flow Good?
As of today, Alnylam Pharmaceuticals, Inc.'s Net Debt to Free Cash Flow is (91.5x), which is lower than industry median of 0.9x. It indicates that Alnylam Pharmaceuticals, Inc.'s Net Debt to Free Cash Flow is Good.